Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2014

View Archived Issues

Phase II results for the influenza A/H7N9 vaccine in combination with an adjuvant

Shionogi recaps highlights of second quarter of fiscal 2014

Novel genetic biomarkers of human malformation disorders

Sumitomo Dainippon Pharma reviews second quarter of fiscal 2014

Sanofi presents highlights of third quarter 2014

Researchers present novel targets and biomarkers in pancreatic cancer

FDA orphan drug status granted to oprozomib for multiple myeloma

Sodium thiosulfate designated orphan drug by the FDA

Glioma candidate pritumumab receives U.S. orphan drug designation

MPDL-3280A well tolerated in phase Ia trial in patients with mRCC

EMA publishes revised guideline on biosimilars

EMA releases third and final module on influenza vaccine guidance for public consultation

Chugai licenses EpiVax de-immunization technologies to optimize biologics pipeline

Swiss approval to begin Ebola vaccine trial

Award supports Verona Pharma's exploration of RPL-554 for cystic fibrosis

New PDE4B inhibitors reported by Gruenenthal

Esteve presents novel ligands of sigma receptors

Guangzhou Baiyunshan Pharmaceutical synthesizes tricyclic quinolones

Canadian company presents CRP40 fragments for neurological disorders

Glenmark Pharmaceuticals reports novel mPGES-1 inhibitors

New GnRH receptor antagonists discovered at Bayer Schering Pharma

Salix and Pharming launch Ruconest in the U.S. for acute angioedema attacks in HAE

Novartis plans phase I/II trial of Wnt-targeting drug regimen in BRAF-mutant colorectal cancer

Arena Pharmaceuticals to test APD-811 in patients with pulmonary arterial hypertension

Nymox's NX-1207 fails to achieve efficacy endpoints in phase III BPH trials

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...